Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Brenda Bartman on May 28th, 2026

Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $5.00.

A number of brokerages have weighed in on CGEN. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a report on Monday, April 20th. Lake Street Capital began coverage on shares of Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price on the stock. Truist Financial raised shares of Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Leerink Partners reduced their target price on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, May 21st. Finally, Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd.

View Our Latest Stock Analysis on CGEN

Institutional Investors Weigh In On Compugen

Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in shares of Compugen by 12.1% in the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock worth $3,478,000 after buying an additional 176,088 shares during the last quarter. State Street Corp lifted its holdings in Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 14,701 shares during the last quarter. Jane Street Group LLC lifted its holdings in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares during the last quarter. Two Sigma Investments LP boosted its position in Compugen by 10.6% during the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares during the period. Finally, Marshall Wace LLP grew its holdings in Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares during the last quarter. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Compugen Trading Up 4.2%

NASDAQ CGEN opened at $2.76 on Thursday. The company has a 50-day moving average price of $2.58 and a two-hundred day moving average price of $2.05. Compugen has a 52 week low of $1.29 and a 52 week high of $3.23. The stock has a market cap of $260.96 million, a price-to-earnings ratio of 7.46 and a beta of 2.79.

Compugen (NASDAQ:CGEN – Get Free Report) last issued its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Compugen had a net margin of 47.97% and a return on equity of 47.72%. The company had revenue of $2.18 million for the quarter, compared to the consensus estimate of $1.57 million. As a group, equities research analysts expect that Compugen will post -0.28 earnings per share for the current fiscal year.

About Compugen

(Get Free Report)

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.